Amgen, Inc. (AMGN), Celgene Corporation (CELG) & More Biotech Madness!

Page 2 of 2

Gilead Sciences, Inc. (NASDAQ:GILD) is a very successful biotech company with 2012 revenues of $9.7 Billion. Gilead Sciences, Inc. (NASDAQ:GILD)’s growth over the last decade has been excellent, with sales increasing by 1000%.income increasing nicely as well. Gilead has a very large number of successful products currently on the market. Gilead’s pipeline consist of a wide variety of new product candidates including Sofosbuvir (Liver Diseases/HIV), Idelalisib (Oncology/Inflammation), Aztreonam (Respiratory), and Ranolazine (Cardiovascular). The following is a breakdown of Gilead’s current products:

GILEAD PRODUCTS TREATMENT TYPE 2012 PRODUCT SALES % INCREASE OVER 2011
Atripla HIV $3.57 Billion 11%
Truvada HIV $3.18 Billion 11%
Viread HIV $849 Million 15%
Complera/Eviplera HIV $342 Million 783%
Stribild HIV $58 Million No 2011 Sales
Letairis Cardiovascular $410 Million 40%
Ranexa Cardiovascular $373 Million 17%
AmBisome Infectious Diseases $347 Million 5%
Cayston Respiratory $107 Million 17%
TOTAL PRODUCT SALES $9.4 Billion 16%

Cubist Pharmaceuticals Inc (NASDAQ:CBST) is this years Cinderella company with 2012 revenues of $926 Million and net income of $128 Milion. Cubist’s sales and earnings have skyrocketed from only $3.4 Million in revenues in 2003. Cubist Pharmaceuticals Inc (NASDAQ:CBST) is mush smaller than the rest of the Final Four companies but has enormous growth potential. Cubist’s pipeline is highlighted by Cefolozane/Tazobactam (Infections), Surotomycin (CDAD), and Bevenopran (Pain), which are all currently in Phase III. The following is a breakdown of Cubist Pharmaceuticals products:

CUBIST PRODUCTS TREATMENT TYPE 2012 SALES % OVER 2011
Cubicin $860 Million 16%
Entereg $40 Million 1500%
TOTAL PRODUCT SALES $900 MILLION 22%

Greg Williamson owns shares of Amgen, Celgene, and Cubist Pharmaceuticals. The Motley Fool recommends Cubist Pharmaceuticals, Celgene and Gilead Sciences.

Page 2 of 2